Table 1.

Overview of tumor outcomes for all treatments in this study

A. Treatments, survival, and melanocytic tumors
Neonatal treatment, d3 (4, 5) ^†	Adult treatment, d28-end	Ink4a	Survival (d)	Melanomas	Nevi
Neonatal treatment, d3 (4, 5) ^†	Adult treatment, d28-end		Survival (d)		n⁻⁻/n⁺⁻/n⁺⁺^‡		∑n	∑n	t_m^§	Yield ^∥
Experiment 1A ^¶
1: 10 μg DMBA	None	12/12/0	226	0	59	108 *	0.83 *
2: 10 μg DMBA	25 μg TPA 2×/wk	13/13/0	216	0	133	82^ns	2.08^ns
3: 10 μg DMBA	35.7 J/m² UV/d	12/11/0	138	0	47	84^ns	0.85 *
4: 10 μg DMBA	250 J/m²UV/wk	7/8/0	120	0	62	66 ^¶	3.00 ^¶
5: 10 μg DMBA	375 J/m² UV/2wk	11/6/0	139	0	132	52 ***	4.71^ns
6: 10 μg DMBA	375 J/m² UV/2wk	0/8/16	160	1	142	62^ns	3.74^ns
Experiment 1B ^††
7: None	None	13/15/0	284	0	16	432 ***	0.00 ***
8: 250 J/m² UV	None	8/7/0	256	0	13	300 ***	0.13 **
9: None	375 J/m² UV/2wk	13/6/0	190	0	48	146^ns	0.21^ns
10: 250 J/m² UV	375 J/m² UV/2wk	10/8/0	171	0	48	88 **	0.83 ^††
11: 250 J/m² UV	35.7 J/m² UV/d	7/11/6 ^‡‡	143	0	23	152 ^‡‡	0.61 *
Experiment 2 ^§§
12: 100 μg DMBA	3,000 J/m² UV/2wk	7/12/0	140	1	808	51 ***	32.6 ***
13: 2,000 J/m² UV	3,000 J/m² UV/2wk	14/13/0	235	1	53	205^ns	0.26^ns
14: None	3,000 J/m² UV/2wk	9/11/0	254	3	53	195 ^§§	0 ^§§
15: 10 μg DMBA	375 J/m² UV/2wk	4/6/7	229	0	18	133^ns	0^ns

B. Outcomes of nonmelanocytic tumors
Treatment ^∥∥	Papillomas					Cysts					SCCs			Sarcomas	GL	OT
Treatment ^∥∥		∑n	t_m	Yield ^∥	∑n	t_m	Yield ^∥	∑n	t_m	∑n	t_m	∑n	∑n
1	74	133 **	0.67^ns	19	175^ns	0.33^ns	3	448 **	1	— *^, ^¶¶	12	12
2	212	82^ns	2.50^ns	10	—^ns	0.27^ns	4	— **	3	— **	5	6
3	287	98^ns	0.82^ns	9	172^ns	0.13^ns	13	158^ns	4	— *	7	11
4	64	66 ^¶	2.08 ^¶	2	— ^¶	0 ^¶	5	186 ^¶	5	175 ^¶	2	6
5	109	80^ns	1.00^ns	6	238^ns	0.12^ns	8	—^ns	5	224^ns	3	10
6	245	90^ns	1.42^ns	2	—^ns	0.05^ns	6	253^ns	0	—^ns	5	4
7	5	— ***	0.00 **	17	408^ns	0.04^ns	1	— *	1	— **	13	9
8	14	287 ***	0.33^ns	40	115^ns	1.67 *	1	— *	1	— *	9	3
9	94	111^ns	1.58^ns	24	133^ns	0.63^ns	5	275^ns	0	— *	8	5
10	93	102 ^††	1.50 ^††	9	— ^††	0.44 ^††	3	285 ^††	6	336 ^††	10	10
11	183	96 *	3.00 **	42	103 **	1.17^ns	16	— *	1	—	4	1
12	707	51 ***	31.1 ***	26	167^ns	0.63^ns	5	385^ns	19	153 ***	6	10
13	27	275^ns	0^ns	114	83 ***	2.04 ***	0	—^ns	20	282 **	3	6
14	102	231 ^§§	0.05 ^§§	25	175 ^§§	0 ^§§	9	— ^§§	5	— ^§§	8	7
15	55	119 **	1.20^ns	5	— *	0.20^ns	1	—^ns	9	325 *	1	0

NOTE: Levels of significance for yields were obtained by ANOVA and for tumor-free survival by Cox regression (corrected for genotype effects).
Abbreviations: GL, generalized lymphoma; OT, other tumors such as heamangiomas, papillomas of the conjunctiva, lung, brain, and colorectal tumors; ∑n, total number of tumors observed per group; ns, not significant.
↵* DMBA treatment at day 3; UVB treatment at days 3, 4, and 5.
↵† Numbers of Ink4a/Arf knockouts, heterozygotes, and wild types per group. All animals in experiment 1 were Xpa^−/−; all animals in experiment 2 were Xpa^+/+.
↵‡ t_m values were obtained from Kaplan-Meier plots.
↵§ Yields were compared at 98 days (experiment 1A) or 140 days (experiments 1B and 2).
↵∥ For statistics, the group exposed weekly to 250 J/m² UV was used as reference group.
↵¶ Level of significance of <0.05.
↵** Level of significance of <0.001.
↵†† For statistics, the group exposed neonatally to 250 J/m² and in adulthood to 375 J/m² UV per fortnight was used as reference group.
↵‡‡ Level of significance of <0.01.
↵§§ For uniformity, statistical comparisons are based on homozygous knockouts and heterozygotes only.
↵∥∥ For statistics, the group sham exposed neonatally and to 3,000 J/m² UV per fortnight in adulthood was used as reference group.
↵¶¶ Numbers refer to Table 1A.
↵*** Could not be calculated (percentage of affected animals never reached 50).